Changeflow GovPing Healthcare & Life Sciences CVB1 Purification Method Using Heparin Affinity
Routine Notice Added Final

CVB1 Purification Method Using Heparin Affinity

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

Hangzhou Yangshengtang Biopharma Co., Ltd. has filed US Patent Application US20260109955A1 for a method of purifying coxsackievirus B1 (CVB1) using heparin affinity chromatography. The application names Lisheng Yang, Bing Liu, Tianyu Ding, Chengfa Ji, Limin Wang, and Wei Shi as inventors and was published on April 23, 2026. The filing date was November 30, 2023, with application number 18860522.

“The present invention relates to a method for separating and purifying CVB1, and particularly, relates to a method for purifying CVB1 virus by using a heparin affinity medium.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 263 changes logged to date.

What changed

The USPTO has published patent application US20260109955A1 for a method of separating and purifying CVB1 virus using a heparin affinity medium. This is a patent application publication, not a granted patent, and does not confer any enforceable rights. Competitors in the viral vaccine, therapeutic, or diagnostic space involving coxsackievirus B1 should monitor this application's prosecution to assess potential future IP landscape changes.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHOD FOR SEPARATING AND PURIFYING CVB1

Application US20260109955A1 Kind: A1 Apr 23, 2026

Assignee

Hangzhou Yangshengtang Biopharma Co., Ltd.

Inventors

Lisheng Yang, Bing Liu, Tianyu Ding, Chengfa Ji, Limin Wang, Wei Shi

Abstract

The present invention relates to a method for separating and purifying CVB1, and particularly, relates to a method for purifying CVB1 virus by using a heparin affinity medium.

CPC Classifications

C12N 7/00 B01D 15/3823 B01D 15/3847 B01D 61/145 C12N 2770/32351

Filing Date

2023-11-30

Application No.

18860522

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Biotechnology companies Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Virus purification
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!